Background: Primary open angle glaucoma remains a high magnitude healthcare problem due to its prevalence and chronicity. The real world scenario of anti glaucoma medical therapy needs periodical auditing as far as drug prescriptions are concerned for formulation of treatment guidelines. Few studies from India have taken a longitudinal approach in this respect. This study was undertaken to identify such lacunae.Methods: This was an open label, prospective, observational study. Each treatment naive patient was followed up for a period of 6 months, where their prescriptions were scanned for the type of the anti glaucoma medications, total number of medications, route of administration, their duration of use and their frequency of dosage and c...
Purpose: To investigate the trends and progresses in glaucoma research by searching two major clinic...
<p><strong>The purpose of this paper </strong>is to assess regimens administered for treatment of pr...
This study was sponsored by Allergan (prior to its acquisition by AbbVie). This research was further...
Background: In view of the high prevalence rates and the fact that medication is the primary line of...
Background: According to World Health Organization (WHO) studies Glaucoma is a chronic progressive s...
Objective: To study the drug utilization pattern in patients suffering from primary open-angle glauc...
Glaucoma is a condition in which distinctive changes occur in the optic nerve and visual field. In g...
Glaucoma affecting 60 million people all over the world and it will be 80 million till 2020. There a...
Aim: To study the prescribing patterns and cost analysis of anti glaucoma medications in a tertiary ...
AIM:To document the change in pattern of topical anti-glaucoma medicine by retrospective analysis in...
Glaucoma is one of the leading causes of blindness worldwide. The main characteristic features inclu...
The purpose of this review is to discuss the topics relevant to the use of intraocular pressure-lowe...
Primary open angle glaucoma (POAG) is a leading cause of blindness with no known cure. Management of...
Glaucoma is a group of diseases, characterized by a progressive form of optic nerve damage. Current ...
Background: As we know primary open angle glaucoma need lifelong treatment. It possess financial bur...
Purpose: To investigate the trends and progresses in glaucoma research by searching two major clinic...
<p><strong>The purpose of this paper </strong>is to assess regimens administered for treatment of pr...
This study was sponsored by Allergan (prior to its acquisition by AbbVie). This research was further...
Background: In view of the high prevalence rates and the fact that medication is the primary line of...
Background: According to World Health Organization (WHO) studies Glaucoma is a chronic progressive s...
Objective: To study the drug utilization pattern in patients suffering from primary open-angle glauc...
Glaucoma is a condition in which distinctive changes occur in the optic nerve and visual field. In g...
Glaucoma affecting 60 million people all over the world and it will be 80 million till 2020. There a...
Aim: To study the prescribing patterns and cost analysis of anti glaucoma medications in a tertiary ...
AIM:To document the change in pattern of topical anti-glaucoma medicine by retrospective analysis in...
Glaucoma is one of the leading causes of blindness worldwide. The main characteristic features inclu...
The purpose of this review is to discuss the topics relevant to the use of intraocular pressure-lowe...
Primary open angle glaucoma (POAG) is a leading cause of blindness with no known cure. Management of...
Glaucoma is a group of diseases, characterized by a progressive form of optic nerve damage. Current ...
Background: As we know primary open angle glaucoma need lifelong treatment. It possess financial bur...
Purpose: To investigate the trends and progresses in glaucoma research by searching two major clinic...
<p><strong>The purpose of this paper </strong>is to assess regimens administered for treatment of pr...
This study was sponsored by Allergan (prior to its acquisition by AbbVie). This research was further...